HELP Therapeutics’ iPSC-derived cardiomyocytes improved walking distance, myocardial perfusion and heart wall thickening when added to bypass surgery in a 20-patient randomized trial.
They'll be using allogeneic iPSCs to treat neurodegenerative disorders. ALS stem cells can be a tough topic after the Nurown trials... are iPSCs the answer?
BioCardia plans to move forward with enrollment of up to 39 participants in the United States.
The trial leverages Calidi’s innovative virotherapy platform, offering new hope for combating this aggressive form of brain cancer.
Leveraging NYBCe's CDMO subsidiary, the companies plan on bridging the gap between Asian and American manufacturing standards. This collaboration seeks to tackle industry-wide GMP capacity challenges, making advanced cell therapies more accessible...
The collaboration aims to leverage innovative biomanufacturing technology to accelerate personalized therapies for cardiovascular patients worldwide.
BioGenCell's lead candidate BGC101 receives FDA Fast Track Designation, accelerating development of its personalized cell therapy to prevent amputations in severe CLTI patients.
Allogene Therapeutics' dual-targeted CAR T therapy, ALLO-329, receives three FDA Fast Track designations, accelerating development for severe autoimmune conditions including lupus, myositis, and systemic sclerosis.
The funds will help expand and secure Canada's cell based therapy supply chain.
The new Princeton facility will boost BioCentriq's capacity, helping clients accelerate innovative cell therapies from development to commercialization.
A significant milestone for the stem cell industry, likely paving the way for future stem cell based therapies.
The amended IND application moves NurOwn® closer to initiation of the pivotal Phase 3b clinical trial for ALS patients.
This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.
Joseph Spine Institute launches its Center for Regenerative Spine Medicine in Tampa, offering minimally invasive stem cell therapies for chronic spinal conditions.
Clinical trials involving eight patients showed improvements in symptoms and cardiac function.
Cellino has successfully manufactured and delivered patient-specific autologous induced pluripotent stem cell (iPSC) lines from four donors to Matricelf for spinal cord injury treatment.
Nature Cell Co., Ltd. announced that its cell therapy product, JointStem, has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA, marking a first for a Korean company in this field....
New funds aim to advance Garuda’s pipeline toward clinical trials, expand manufacturing capabilities, and support operational growth.
The interest in stem cells is booming and it may become legal in the USA shortly... however, there's a lot of conflicting information about the products, both from the companies selling them...
Traumatic brain injury (TBI) occurs when trauma disrupts normal brain functions, potentially causing severe physical, cognitive, and emotional impairments. Researchers are exploring stem cells as a possible treatment because these cells might...
The National Stem Cell Foundation (NSCF) has received a $3.1 million grant from NASA to further its research on neurodegenerative diseases aboard the International Space Station (ISS). This funding will support additional...
Recent clinical data presented at the AAOS 2025 Annual Meeting in San Diego suggest that MEDIPOST's stem cell therapy, Cartistem, may offer a more effective treatment for severe knee osteoarthritis (OA) compared...
MIT researchers have developed a new method to convert skin cells directly into neurons, bypassing the pluripotent stem cell stage in iPSC development. This technique, demonstrated in mouse cells, could potentially lead...
Terumo Blood and Cell Technologies (Terumo BCT) and Akron Bio say they've completed a collaborative study demonstrating equivalency between research-use-only (RUO) and Good Manufacturing Practices (GMP)-grade fibronectin for expanding mesenchymal stem cells...
In March this year, a ScienceDaily article reported that Mass General is pioneering a Phase 1 clinical trial advancing stem cell therapies for Parkinson's disease. The trial involves reprogramming patients' own stem...
AMSBIO has introduced its GMP-grade StemFit® for Differentiation, a medium designed for the differentiation of human induced pluripotent stem (hiPS) and embryonic stem (hES) cells. This formulation, now compliant with Good Manufacturing...
